AbCellera Biologics Inc. · Q4 2023
ReportedFeb 20, 2024
Period endedDec 31, 2023
The quarter in short
Revenue $9M, up 39.1% on the quarter. EPS −$0.16, down 60.0% on the quarter. Free cash flow −$34M, down 66.6% on the quarter.
Reported this quarter
Revenue
$9M
QoQ +39.1%
YoY —
EPS
−$0.16
QoQ −60.0%
YoY —
Free Cash Flow
−$34M
QoQ −66.6%
YoY —
FCF Margin
-370.9%
QoQ −61.2 pp
YoY —
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1703057.
HTML
8-K results announcement
Filed Feb 20, 2024
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
175 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
20 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2023, filed Feb 20, 2024
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure ABCL has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q4 2023, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings